Prasad S. Reply: UGN-102 for Recurrent Low-Grade Intermediate-Risk Non-Muscle-Invasive Bladder Cancer: A 24-Month Duration of Response Results from the Phase 3 ENVISION Trial. J Urol 2026 Jun 2:101097JU0000000000005128. doi: 10.1097/JU.0000000000005128.
PMID: 42229364